“USPI’s M&A engine under the Tenet umbrella continues to be an industry-leading differentiator,” CEO Saum Sutaria, MD, said on the call. “In 2022, we added 45 centers to the portfolio through M&A and de novo development, in addition to the [SurgCenter Development] centers.”
The company is also continuing to build surgery centers through its USPI development team and from its partnership with Towson, Md.-based SurgCenter Development. And in June, USPI and United Urology Group formed a partnership for 22 ASCs. According to the earnings call, USPI has 22 ASCs in active syndication or under construction.
The company is also focusing on USPI’s value-based offerings.
“Our services are generally 30 percent to 50 percent more affordable than similar services delivered in a hospital setting,” Dr. Sutaria said. “The linkage to our hospital business creates an unquestionably superior platform from which to draw talent, operating expertise and scale benefits.”
Last year, USPI reported $1.3 billion in EBITDA, with strong margins at 40.9 percent, according to the company’s financial report. USPI’s same-facility revenues grew 4.6 percent in 2022, which is in the range of the company’s long-term, top-line growth goal of between 4 percent and 6 percent.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
